Nav: Home

New study: Leading cause of blindness could be prevented or delayed

November 09, 2015

Clarksburg MD - In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.

The findings, published in the American Journal of Medicine, are a groundbreaking effort in the fight against age-related macular degeneration (AMD), which affects as many as 11 million Americans. AMD hinders central vision, and even when it does not lead to blindness it can severely reduce the ability to read, drive, and recognize faces.

In the study, supported in part by BrightFocus Foundation, researchers discovered a biological connection between darker pigmented eyes, which are known to be resistant to AMD, and increased levels of a chemical called L-DOPA in those eyes. Since L-DOPA is frequently prescribed for Parkinson's patients, the researchers wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson's or other diseases were protected from AMD. By combing through massive databases of medical chart data, they reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.

"Rather than looking at what might cause AMD, we instead wondered why certain people are protected from AMD. This approach had never been done before," says senior author Brian McKay of the University of Arizona.

The research findings are based off an analysis of the medical records of 37,000 patients at the Marshfield Clinic in Wisconsin. Because the average age of those given L-DOPA is 67, while the average age of AMD diagnosis is 71, scientists were able to effectively track patterns. These major findings were then confirmed by reviewing a data set of 87 million patients. In this large scale data set, L-DOPA also delayed or prevented AMD from progressing to its "wet" form, the most devastating form of the disease.

"This exciting breakthrough shows the power of scientific discovery to give hope to millions of people across the nation and the world. Their methodology is a reminder that 'big data' is not a buzzword - it is a bold and innovative new approach to science," said BrightFocus president and CEO Stacy Pagos Haller.

The next steps for the team of scientists is to launch a clinical trial to further test the ability of this drug to prevent AMD. The title of their research paper is "Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration."
-end-
BrightFocus Foundation drives innovative research worldwide and promotes awareness of Alzheimer's, macular degeneration, and glaucoma. BrightFocus, which earlier this year announced a record $11 million in new science to cure diseases of mind and sight, is currently managing a global portfolio of over 150 research projects. For more information http://www.BrightFocus.org or 800/437-2423.

BrightFocus Foundation

Related Blindness Articles:

Study sheds light on parasite that causes river blindness
The parasite that causes river blindness infects about 37 million people in parts of Africa and Latin America, causing blindness and other major eye and skin diseases in about 5 million of them.
After blindness, the adult brain can learn to see again
More than 40 million people worldwide are blind, and many of them reach this condition after many years of slow and progressive retinal degeneration.
Risk of blindness from spine surgery down significantly
The risk of blindness caused by spinal fusion, one of the most common surgeries performed in the US, has dropped almost three-fold since the late 1990s, according to the largest study of the topic to date.
Disease that causes blindness in children tied to new gene
Northwestern Medicine and University of Wisconsin-Madison (UW) scientists have identified a gene that causes severe glaucoma in children.
Prevalence of visual impairment, blindness expected to increase in US
An aging Baby Boomer population in the US will contribute to an expected doubling of the prevalence of visual impairment and blindness in the next 35 years, according to a study published online by JAMA Ophthalmology.
Starving eye cells contribute to blindness in elders
Age-related macular degeneration (AMD) is the leading cause of visual impairment in people over 50 in developed countries.
New study: Leading cause of blindness could be prevented or delayed
In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.
Up to 1 billion people at risk of blindness by 2050
5 billion are expected to be myopic (short-sighted) by 2050.
Researchers study potential cures for congenital blindness
University of Akron assistant chemistry professor Dr. Adam W. Smith and his team received a grant for research that could have promising results for curing congenital blindness.
Fortified against blindness
In South Africa, sweet potatoes are a traditional crop for rural families.

Related Blindness Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".